NovoCure Ltd

NASDAQ:NVCR   3:59:51 PM EDT
72.40
+0.37 (+0.51%)
Products, Regulatory

Zai Lab And Novocure Announce Ef-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together With Standard-Of-Care Chemotherapy Meets Primary Endpoint For First-Line Treatment Of Gastric Ca

Published: 06/03/2022 12:14 GMT
NovoCure Ltd (NVCR) - Zai Lab and Novocure Announce Ef-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together With Standard-of-care Chemotherapy Meets Primary Endpoint for First-line Treatment of Gastric Cancer.
Zai Lab Ltd - Ttfields Therapy Was Well Tolerated, With No Increase in Systemic Toxicity of Xelox Chemotherapy Regimen Or Combination Regimen.
Zai Lab Ltd - No High-grade Skin Toxicities Were Reported in Ttfields Therapy.